Tularik announced after Monday's close that the U.S. Food and Drug Administration has green-lighted the design of what could be the final clinical tests for the South San Francisco-based biotech's liver cancer drug, T67.
ETC-216 will not be a drug for all the millions of people who suffer from severe coronary artery disease, even if it does eventually get a green light from the U.S. Food and Drug Administration.